Hims & Hers Health, Inc. $HIMS Stock Position Raised by Fiduciary Alliance LLC

Key Points

• Fiduciary Alliance LLC has increased its position in Hims & Hers Health, Inc. by 120.4%, now holding 109,253 shares valued at approximately $5.4 million.
• In the latest quarter, Hims & Hers reported $0.17 EPS, slightly missing expectations, with revenues of $544.83 million, a 72.6% increase year-over-year.
• Insider transactions included CEO Andrew Dudum selling 660,000 shares worth over $33 million, which represented a 22.96% decrease in his holdings.

Fiduciary Alliance LLC increased its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 120.4% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 109,253 shares of the company's stock after purchasing an additional 59,686 shares during the period. Fiduciary Alliance LLC's holdings in Hims & Hers Health were worth $5,446,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health in the first quarter worth $30,000. UMB Bank n.a. lifted its holdings in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Hims & Hers Health during the 1st quarter worth $41,000. Larson Financial Group LLC grew its position in shares of Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after purchasing an additional 458 shares during the last quarter. Finally, Webster Bank N. A. grew its holdings in Hims & Hers Health by 229.1% in the 2nd quarter. Webster Bank N. A. now owns 905 shares of the company's stock valued at $45,000 after buying an additional 630 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $54.02 on Tuesday. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The business's fifty day moving average price is $50.38 and its two-hundred day moving average price is $45.36. Hims & Hers Health, Inc. has a fifty-two week low of $15.73 and a fifty-two week high of $72.98. The stock has a market capitalization of $12.21 billion, a price-to-earnings ratio of 67.53, a price-to-earnings-growth ratio of 3.75 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same period in the previous year, the business posted $0.06 earnings per share. The firm's revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Wall Street Zen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. UBS Group set a $30.00 target price on Hims & Hers Health in a research report on Monday, June 23rd. Canaccord Genuity Group restated a "buy" rating and set a $68.00 price target on shares of Hims & Hers Health in a research note on Friday. Finally, Morgan Stanley restated an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Reduce" and a consensus target price of $38.92.

Insider Activity

In other news, CEO Andrew Dudum sold 660,000 shares of the business's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares of the company's stock, valued at $112,023,016.02. The trade was a 22.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael Chi sold 13,750 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $56.00, for a total value of $770,000.00. Following the sale, the insider directly owned 278,654 shares of the company's stock, valued at $15,604,624. This represents a 4.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,110,347 shares of company stock valued at $55,342,532 in the last ninety days. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.